Elanco Reports Strong Q1 Results, Raises Full-Year Revenue, EBITDA, and EPS Guidance

summarizeSummary

Elanco Animal Health reported robust first-quarter results, exceeding expectations and leading the company to raise its full-year financial guidance across revenue, Adjusted EBITDA, and Adjusted EPS, while also improving its net leverage ratio target.

check_boxKey Events · Earnings and Guidance · ELAN

• Strong Q1 Financial Performance

  Elanco reported first-quarter revenue of $1,371 million, a 15% increase year-over-year (10% organic constant currency growth), and Adjusted EPS of $0.40.

• Raised Full-Year Guidance

  The company increased its full-year 2026 revenue guidance to $5.01 billion - $5.085 billion, Adjusted EBITDA to $975 million - $1.005 billion, and Adjusted EPS to $1.03 - $1.09.

• Improved Leverage Target

  Elanco improved its year-end net leverage ratio target to 3.0x - 3.2x Adjusted EBITDA, indicating a strengthening financial position.

• Innovation Success

  Key products like Zenrelia achieved trailing 4-quarter blockbuster status, and Credelio Quattro demonstrated accelerating market share gains.

auto_awesomeAnalysis · ELAN · Life Sciences

Elanco's first-quarter performance demonstrates significant operational momentum, with reported revenue increasing 15% year-over-year and organic constant currency growth of 10%. The company's decision to raise its full-year outlook for revenue, Adjusted EBITDA, and Adjusted EPS, alongside an improved year-end net leverage ratio target, signals strong confidence in its innovation-led strategy and financial health. This comprehensive "beat and raise" quarter, driven by new product success like Zenrelia and Credelio Quattro, suggests a positive trajectory for the company, especially following a net loss in the prior fiscal year. Investors should view this as a strong indicator of improving fundamentals and execution.